PL3019167T3 - Leczenie podwyższonych poziomów eozynofili i/lub bazofili - Google Patents

Leczenie podwyższonych poziomów eozynofili i/lub bazofili

Info

Publication number
PL3019167T3
PL3019167T3 PL14822432T PL14822432T PL3019167T3 PL 3019167 T3 PL3019167 T3 PL 3019167T3 PL 14822432 T PL14822432 T PL 14822432T PL 14822432 T PL14822432 T PL 14822432T PL 3019167 T3 PL3019167 T3 PL 3019167T3
Authority
PL
Poland
Prior art keywords
basophils
eosinophils
elevated levels
treating elevated
treating
Prior art date
Application number
PL14822432T
Other languages
English (en)
Inventor
Michael E. Bozik
Gregory HEBRANK
Jr. Thomas Petzinger
Steven Dworetzky
Wildon Farwell
Original Assignee
Knopp Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/966,229 external-priority patent/US9468630B2/en
Application filed by Knopp Biosciences Llc filed Critical Knopp Biosciences Llc
Publication of PL3019167T3 publication Critical patent/PL3019167T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PL14822432T 2013-07-12 2014-07-11 Leczenie podwyższonych poziomów eozynofili i/lub bazofili PL3019167T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201361845944P 2013-07-12 2013-07-12
US201361859158P 2013-07-26 2013-07-26
US201361865118P 2013-08-12 2013-08-12
US13/966,229 US9468630B2 (en) 2013-07-12 2013-08-13 Compositions and methods for treating conditions related to increased eosinophils
USPCT/US2013/054804 2013-08-13
US201461987117P 2014-05-01 2014-05-01
PCT/US2014/046380 WO2015006708A1 (en) 2013-07-12 2014-07-11 Treating elevated levels of eosinophils and/or basophils
EP14822432.2A EP3019167B1 (en) 2013-07-12 2014-07-11 Treating elevated levels of eosinophils and/or basophils

Publications (1)

Publication Number Publication Date
PL3019167T3 true PL3019167T3 (pl) 2021-06-14

Family

ID=52280641

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14822432T PL3019167T3 (pl) 2013-07-12 2014-07-11 Leczenie podwyższonych poziomów eozynofili i/lub bazofili

Country Status (19)

Country Link
US (5) US10828284B2 (pl)
EP (2) EP3838271A1 (pl)
JP (1) JP6329717B2 (pl)
CN (1) CN105764507B (pl)
AU (1) AU2014287067C1 (pl)
BR (1) BR112016000627B1 (pl)
CA (1) CA2918035C (pl)
CY (1) CY1123914T1 (pl)
DK (1) DK3019167T3 (pl)
ES (1) ES2858500T3 (pl)
HR (1) HRP20210368T1 (pl)
HU (1) HUE054185T2 (pl)
IL (1) IL243508B (pl)
LT (1) LT3019167T (pl)
PL (1) PL3019167T3 (pl)
PT (1) PT3019167T (pl)
RS (1) RS61539B1 (pl)
SI (1) SI3019167T1 (pl)
WO (1) WO2015006708A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
CN102186350A (zh) 2008-08-19 2011-09-14 诺普神经科学股份有限公司 使用(r)-普拉克索的组合物与方法
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
BR112016000627B1 (pt) 2013-07-12 2022-02-08 Knopp Biosciences Llc Uso de dexpramipexol ou um sal farmaceuticamente aceitável do mesmo
HUE055850T2 (hu) 2013-08-13 2022-01-28 Knopp Biosciences Llc Készítmények és módszerek a krónikus urticaria (csalánkiütés) kezelésére
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
IT201600077186A1 (it) * 2016-07-22 2018-01-22 Alberto Chiarugi Uso di agente per indurre broncodilatazione
CA3052190A1 (en) * 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
AU2021322255A1 (en) * 2020-08-05 2023-02-23 Areteia Therapeutics, Inc. Use of dexpramipexole for the treatment of moderate to severe asthma
WO2023091608A2 (en) * 2021-11-18 2023-05-25 Memorial Sloan-Kettering Cancer Center Methods for treating anti-cancer drug-related skin rashes using benralizumab

Family Cites Families (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US760704A (en) * 1903-11-14 1904-05-24 Frederick W Saworski Bobbin and spindle connector.
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4395859A (en) 1980-06-05 1983-08-02 State Of Illinois, Department Of Transportation Method and apparatus for securing an object to a support structure
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4725272A (en) 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
US4849226A (en) 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4435180A (en) 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
US4559222A (en) 1983-05-04 1985-12-17 Alza Corporation Matrix composition for transdermal therapeutic system
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4704282A (en) 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
JPS6155377A (ja) 1984-08-25 1986-03-19 Shimadzu Corp 回転形流体エネルギ変換機
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
DE3572485D1 (en) 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4904475A (en) 1985-05-03 1990-02-27 Alza Corporation Transdermal delivery of drugs from an aqueous reservoir
US4645502A (en) 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4698062A (en) 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
ATE71287T1 (de) 1986-06-13 1992-01-15 Alza Corp Aktivierung eines transdermalen drogenabgabesystems durch feuchtigkeit.
US4938759A (en) 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US5344656A (en) 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4908027A (en) 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US5071656A (en) 1987-03-05 1991-12-10 Alza Corporation Delayed onset transdermal delivery device
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4917895A (en) 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US4781924A (en) 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US5004610A (en) 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
DE69009540T2 (de) 1989-03-15 1994-09-29 Nitto Denko Corp Arzneimittel enthaltendes Heftpflaster.
US5024843A (en) 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US5091190A (en) 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5591454A (en) 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5314694A (en) 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
US5122382A (en) 1990-10-29 1992-06-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
FR2688138B1 (fr) 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
WO1993023025A1 (en) 1992-05-13 1993-11-25 Alza Corporation Transdermal administration of oxybutynin
US5792664A (en) 1992-05-29 1998-08-11 The Rockefeller University Methods for producing and analyzing biopolymer ladders
ATE427493T1 (de) 1992-05-29 2009-04-15 Univ Rockefeller Verfahren zur bestimmung der folge von peptiden unter verwendung eines massenspektrometers
EP0700521B1 (en) 1993-05-28 2003-06-04 Baylor College Of Medicine Method and mass spectrometer for desorption and ionization of analytes
US6566386B2 (en) 1993-08-09 2003-05-20 Nippon Zoki Pharmaceutical Co., Ltd. Immunomodulating and antiinflammatory agent
US5442117A (en) 1993-12-13 1995-08-15 Albemarle Corporation Enantiomeric resolution
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5650420A (en) 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5912268A (en) 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
BR9611124A (pt) 1995-10-26 1999-05-11 Sanofi Sa Utilização da 1-(2-naft-2-iletil)-4- (3-trifluorometifenil) -1,2,3,6-tetraidropiridina ou um dos seus sais de adição com ácidos farmaceuticamente aceitáveis composição farmacéutica e método de tratamento da esclerose lateral amiotrófica
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
GB9705428D0 (en) 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US5804215A (en) 1997-03-21 1998-09-08 L. Perrigo Company Transdermal patch disposal system and method
US5883995A (en) 1997-05-20 1999-03-16 Adc Telecommunications, Inc. Fiber connector and adapter
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
KR20010024251A (ko) 1997-09-23 2001-03-26 사이퍼젠 바이오시스템스, 인코오포레이티드 비행 시간형 질량 분석계용 2차 이온 발생기 검출기
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
JP2002510604A (ja) 1998-04-02 2002-04-09 アビセナ グループ， インク． クレアチン化合物及び第二物質の組み合わせを含む組成
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE19830201A1 (de) 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2000006162A1 (de) 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
PL205109B1 (pl) 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
US6776984B1 (en) 1999-08-20 2004-08-17 George R. Schwartz Induced regeneration and repair of damaged neurons and nerve axon myelin
US6541486B1 (en) 1999-06-04 2003-04-01 Elan Pharma International Ltd. Bis-benzimidazole compounds and analogs thereof for inhibiting cell death
DE19938825A1 (de) 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
US6480820B1 (en) 1999-09-20 2002-11-12 Advanced Cochlear Systems, Inc. Method of processing auditory data
US6750235B1 (en) 1999-09-30 2004-06-15 The General Hospital Corporation Pramipexole as a treatment for ***e craving
AU7620600A (en) 1999-09-30 2001-04-30 General Hospital Corporation, The Use of pramipexole as a treatment for ***e craving
TWI283577B (en) 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US20040132788A1 (en) 1999-10-11 2004-07-08 Chabrier De Lassauniere Pierre-Etienne Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
US6443976B1 (en) 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
JP2003523741A (ja) 2000-02-01 2003-08-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ｂｃｌ−２様ポリヌクレオチド、ポリペプチドおよび抗体
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
AU2001262943A1 (en) 2000-04-14 2001-10-30 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
CA2415815A1 (en) 2000-07-06 2002-01-17 Nigel H. Greig Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (de) 2000-08-02 2002-02-14 Daimler Chrysler Ag Anordnung von Bedienelementen
ES2187249B1 (es) 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
AU2001296703A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
US6618138B2 (en) 2000-10-12 2003-09-09 Jed Khoury Scanning fluorescent systems for various diagnostic
AU2002245043B2 (en) 2000-11-16 2006-10-26 Bio-Rad Laboratories, Inc. Method for analyzing mass spectra
US20020177626A1 (en) 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
US7160899B2 (en) 2001-04-09 2007-01-09 Neurosearch A/S Adenosine A2A receptor antangonists combined with neurotrophic activity compounds in the treatment of Parkinson's disease
EP1395695B1 (en) 2001-06-12 2008-12-24 LG Electronics Inc. Full automatic washing machine and method for controlling the same
US20030013120A1 (en) 2001-07-12 2003-01-16 Patz Edward F. System and method for differential protein expression and a diagnostic biomarker discovery system and method using same
GB0117618D0 (en) 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
DE10137082A1 (de) 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
EP2305253A1 (en) 2001-12-11 2011-04-06 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
MY139056A (en) 2001-12-28 2009-08-28 Ab Enzymes Gmbh Microbially-expressed thermotolerant phytase for animal feed
PT1467712E (pt) 2002-01-16 2008-01-09 Boehringer Ingelheim Pharma Comprimido farmacêutico de duas camadas compreendendo telmisartan e hidroclorotiazida
US20030166696A1 (en) 2002-01-24 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pramipexole for the treatment of HIV dementia
RU24834U1 (ru) 2002-02-14 2002-08-27 Закрытое акционерное общество "ЭКО-АТОМ" Устройство для многостадийной обработки воды
EP1482962A4 (en) 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
PT1485078E (pt) 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
DE10213571A1 (de) 2002-03-26 2003-10-23 Lichtwer Pharma Ag Pflanzenextrakte und deren Anwendung
US20040033530A1 (en) 2002-04-08 2004-02-19 Awrey Donald E. High throughput purification, characterization and identification of recombinant proteins
CA2488609A1 (en) 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
KR100505260B1 (ko) 2002-06-28 2005-07-29 노건웅 알레르기를 유발하는 특정 물질에 대한 내성 유도 방법,내성 유도용 키트 및 이들을 이용한 내성 획득 방법
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20050074865A1 (en) 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
GB0221513D0 (en) 2002-09-17 2002-10-23 Generics Uk Ltd Novel compounds and processes
CA2499599A1 (en) 2002-09-17 2004-04-01 New York University Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
GB2394951A (en) 2002-11-04 2004-05-12 Cipla Ltd One pot synthesis of 2,6-diamino-4,5,6,7-tetrahydro-benzothiazole
US6904663B2 (en) 2002-11-04 2005-06-14 Taylor Made Golf Company, Inc. Method for manufacturing a golf club face
US20050202093A1 (en) 2002-12-02 2005-09-15 Kohane Daniel S. Prolonged suppression of electrical activity in excitable tissues
UA79182C2 (en) 2002-12-13 2007-05-25 Basf Ag Method for the production of benzophenones
JP2006516549A (ja) 2002-12-23 2006-07-06 メルク フロスト カナダ アンド カンパニー パーキンソン病の治療用医薬組成物及び治療方法
AU2004228017C1 (en) 2003-03-31 2010-06-03 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7662987B2 (en) 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
DE10333393A1 (de) 2003-07-23 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit dem Wirkstoff Pramipexol
US7365086B2 (en) 2003-07-25 2008-04-29 Synthon Ip Inc. Pramipexole acid addition salts
US20080020028A1 (en) 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
US20050053649A1 (en) 2003-09-08 2005-03-10 Anne-Marie Chalmers Medication delivery device
ITRM20030459A1 (it) 2003-10-07 2005-04-08 Sipa Societa Industrializzazione P Rogettazione A Dispositivo e processo di estrazione di oggetti in materia plastica.
CA2542391A1 (en) 2003-10-23 2005-05-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Biomarkers for amyotrophic lateral sclerosis
CA2560128A1 (en) 2004-03-19 2005-10-06 Dipharma S.P.A. Intermediates for the preparation of pramipexole
US20120253047A1 (en) 2004-03-19 2012-10-04 Dipharma S.P.A. Process for the preparation of (r)-pramipexole
US20050220877A1 (en) 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
US7539203B2 (en) 2004-05-26 2009-05-26 Intel Corporation Multiple channel flow control with first-in-first-out (FIFO) read/write random access memory (RAM)
JP2008502609A (ja) 2004-06-17 2008-01-31 オステオロジックス エイ／エス リウマチおよび関節性疾患の治療改善方法
WO2006012277A2 (en) 2004-06-30 2006-02-02 Amr Technology, Inc. Biocatalytic process for preparing enantiomerically enriched pramipexole
WO2006003471A2 (en) 2004-07-03 2006-01-12 Generics [Uk] Limited Process for the preparation of pramipexole by chiral chromatography
DE102004034987A1 (de) 2004-07-16 2006-02-02 Carl Zeiss Jena Gmbh Lichtrastermikroskop und Verwendung
BRPI0513846A (pt) 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo
EP2431026A1 (en) 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
DE102004044578A1 (de) 2004-09-13 2006-03-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit einer Haftschicht, Verfahren zum Silikonisieren einer Rückschicht des Systems und Verwendung der Rückschicht
US20060069263A1 (en) 2004-09-30 2006-03-30 Irina Gribun Process for the reduction of (S)-2-amino-6-propionamido-4,5,6,7-tetrahydrobenzo-thiazole
WO2006043532A1 (ja) 2004-10-19 2006-04-27 Ono Pharmaceutical Co., Ltd. パーキンソン病治療剤
JP2006143708A (ja) 2004-10-19 2006-06-08 Ono Pharmaceut Co Ltd 神経変性疾患治療用医薬
ME01615B (me) 2004-11-05 2014-09-20 Boehringer Ingelheim Int Dvoslojna tableta koja sadrži telmisartan i amlodipin
US7572596B2 (en) 2004-12-02 2009-08-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Modulation of the neuroendoctrine system as a therapy for motor neuron disease
US20060121619A1 (en) 2004-12-02 2006-06-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Protein biomarkers and therapeutic targets in an animal model for amyotrophic lateral sclerosis
WO2006070406A1 (en) 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
ES2310146B1 (es) 2004-12-30 2009-11-11 Chemagis Ltd. Nuevo procedimiento para preparar pramipexol y su mezcla isomerica optica mediante reduccion con triacetoxiborohidruro de sodio.
JP2008527002A (ja) 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
EP1877079A4 (en) 2005-04-15 2011-08-31 Human Matrix Sciences Llc ELASTIN BINDING PROTEIN LIGANDS DERIVED FROM PLANTS AND METHODS OF USE
CA2607475A1 (en) 2005-04-22 2006-11-02 Genentech, Inc. Method for treating dementia or alzheimer's disease with a cd20 antibody
US20060270742A1 (en) 2005-05-02 2006-11-30 Jane Staunton Compositions and methods for the treatment of neurodegenerative diseases
ES2264378B1 (es) 2005-05-09 2007-11-01 Ragactives, S.L. Procedimiento para la resolucion de 2-amino-6propilamino-4,5,6,7-tetrahidrobenzotiazol y compuestos intermedios.
WO2006126948A1 (en) 2005-05-27 2006-11-30 Astrazeneca Ab Piperidines for the treatment of chemokine mediated diseases
CA2619217A1 (en) 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
US20070203209A1 (en) 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
AU2006305309A1 (en) 2005-10-18 2007-04-26 Ono Pharmaceutical Co., Ltd. Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis
US20080262053A1 (en) 2005-10-18 2008-10-23 Juergen Reess Use of Pramipexole for Treating Moderate to Severe Restless Legs Syndrome (Rls)
WO2007076062A2 (en) 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
PL378587A1 (pl) 2005-12-29 2007-07-09 Instytut Farmaceutyczny Sposób wytwarzania (S)-(-)-2-amino-6-n-propyloamino-4,5,6,7-tetrahydrobenzotiazolu i/lub jego soli
WO2007090882A2 (en) 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
US8017598B2 (en) 2006-05-16 2011-09-13 Knopp Neurosciences, Inc. Compositions of R(+) and S(−) pramipexole and methods of using the same
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
US20070259930A1 (en) 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
EP2497473A1 (en) 2006-05-16 2012-09-12 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of Parkinson's disease and pharmaceutical compositions thereof
KR20090045943A (ko) 2006-08-24 2009-05-08 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 저장 안정성이 높은 프라미펙솔 디하이드로클로라이드 정제의 제조방법
US20080081041A1 (en) 2006-09-29 2008-04-03 Jeffrey Nemeth Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer
WO2008041240A1 (en) 2006-10-03 2008-04-10 Cadila Healthcare Limited Process for preparing (s)-pramipexole and its intermediates
JP2010508252A (ja) 2006-10-30 2010-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング パーキンソン病の治療のためのプラミペキソール又はその塩の使用
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CN101641096A (zh) * 2006-12-14 2010-02-03 诺普神经科学股份有限公司 (r)-普拉克索的组合物以及使用该组合物的方法
WO2008074033A1 (en) 2006-12-14 2008-06-19 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
WO2008104847A2 (en) 2007-02-26 2008-09-04 Wockhardt Research Centre Processes for the preparation of pramipexole and salts thereof
US8519148B2 (en) 2007-03-14 2013-08-27 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
CA2680800A1 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Modified release formulations of (6r)-4,5,6,7-tetrahydro-n6-propyl-2,6-benzothiazole-diamine and methods of using the same
US20110189167A1 (en) 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
JP2008308488A (ja) 2007-05-11 2008-12-25 Santen Pharmaceut Co Ltd 非麦角系の選択的ｄ２受容体アゴニストを有効成分として含有する後眼部疾患の予防又は治療剤
NZ599278A (en) 2007-05-14 2013-12-20 Medimmune Llc Methods of reducing eosinophil levels
ES2441945T3 (es) 2008-03-28 2014-02-07 Glaxosmithkline Llc Métodos de tratamiento
CN102186350A (zh) 2008-08-19 2011-09-14 诺普神经科学股份有限公司 使用(r)-普拉克索的组合物与方法
TWM367342U (en) 2009-05-01 2009-10-21 Advanced Connectek Inc Fiber optics adapter
US8408815B2 (en) 2009-06-18 2013-04-02 Senko Advanced Components, Inc. Optical fiber connector and adapter
BRPI1010084A2 (pt) 2009-06-19 2015-08-25 Knopp Neurosciences Inc Método para tratar esclerose lateral amiotrófica em um paciente
JP2012532191A (ja) 2009-07-06 2012-12-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ［４，６−ビス（ジメチルアミノ）−２−（４−｛［４−（トリフルオロメチル）ベンゾイル］アミノ｝ベンジル）ピリミジン−５−イル］の多形体
US20120134929A1 (en) * 2009-08-06 2012-05-31 Mcgrath Michael S Treatment of macrophage-related disorders
US20130079526A1 (en) 2010-03-03 2013-03-28 Knopp Neurosciences Inc. Synthesis of Chirally Purified Substituted Benzothiazole Diamines
KR20130036227A (ko) 2010-03-31 2013-04-11 인텍스 가부시키가이샤 광원 장치
WO2011150221A2 (en) 2010-05-26 2011-12-01 Knopp Neurosciences, Inc. Compounds and methods of modulating mitochondrial bioenergetic efficiency through an interaction with atp synthase (complex v) and its subunits
WO2012075473A1 (en) 2010-12-03 2012-06-07 Euthymic Bioscience, Inc. Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
US20130052190A1 (en) * 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
US20130059801A1 (en) 2011-08-31 2013-03-07 Catabasis Pharmaceuticals, Inc. Fatty acid amides, compositions and methods of use
WO2013034173A1 (en) 2011-09-06 2013-03-14 Synthon Bv Pramipexole extended release tablets
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
WO2013096870A1 (en) 2011-12-22 2013-06-27 Knopp Neurosciences Inc Compositions and methods for treating amyotrophic lateral sclerosis
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014134569A1 (en) * 2013-02-28 2014-09-04 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
BR112016000627B1 (pt) 2013-07-12 2022-02-08 Knopp Biosciences Llc Uso de dexpramipexol ou um sal farmaceuticamente aceitável do mesmo
JP6115377B2 (ja) 2013-07-24 2017-04-19 Jsr株式会社 樹脂組成物及びレジストパターン形成方法
DE102013108610A1 (de) 2013-08-06 2015-02-12 Rogers Germany Gmbh Metall-Keramik-Substrat sowie Verfahren zum Herstellen eines Metall-Keramik-Substrates
HUE055850T2 (hu) 2013-08-13 2022-01-28 Knopp Biosciences Llc Készítmények és módszerek a krónikus urticaria (csalánkiütés) kezelésére
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
WO2015061777A2 (en) 2013-10-25 2015-04-30 Oral Alpan Therapy for chronic idiopathic urticaria, anaphylaxis and angioedema
PT3973987T (pt) 2014-09-15 2024-04-01 Regeneron Pharma Combinação compreendendo um antagonista de il-4r, um corticoesteroide e um agonista beta2-adrenérgico de ação prolongada para tratar a asma

Also Published As

Publication number Publication date
WO2015006708A1 (en) 2015-01-15
BR112016000627A2 (pl) 2017-07-25
EP3019167A1 (en) 2016-05-18
CN105764507A (zh) 2016-07-13
JP6329717B2 (ja) 2018-05-23
RS61539B1 (sr) 2021-04-29
US20180228777A1 (en) 2018-08-16
US11026928B2 (en) 2021-06-08
EP3019167B1 (en) 2021-02-17
US20210267949A1 (en) 2021-09-02
EP3838271A1 (en) 2021-06-23
AU2014287067A1 (en) 2016-02-04
US10828284B2 (en) 2020-11-10
CY1123914T1 (el) 2022-05-27
US11612589B2 (en) 2023-03-28
CA2918035C (en) 2023-01-03
JP2016523981A (ja) 2016-08-12
ES2858500T3 (es) 2021-09-30
BR112016000627B1 (pt) 2022-02-08
HRP20210368T1 (hr) 2021-04-16
LT3019167T (lt) 2021-03-25
AU2014287067B2 (en) 2019-04-18
HUE054185T2 (hu) 2021-08-30
EP3019167A4 (en) 2017-01-18
US20180271839A1 (en) 2018-09-27
CA2918035A1 (en) 2015-01-15
US20160158205A1 (en) 2016-06-09
CN105764507B (zh) 2019-07-19
IL243508B (en) 2019-02-28
SI3019167T1 (sl) 2021-04-30
DK3019167T3 (da) 2021-03-15
AU2014287067C1 (en) 2019-07-25
US20230277509A1 (en) 2023-09-07
US10383857B2 (en) 2019-08-20
PT3019167T (pt) 2021-03-04

Similar Documents

Publication Publication Date Title
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
IL243508B (en) Treatment of high levels of eosinophils and/or basophils
EP2970317A4 (en) PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
EP2981623A4 (en) SYSTEMS AND METHOD FOR THE ASSESSMENT OF MICROBIOMES AND TREATMENTS THEREOF
EP3035910A4 (en) COMPOSITIONS AND METHODS FOR CAPILLARY TREATMENT
GB201320723D0 (en) Composition and methods of treatment
GB201612518D0 (en) Devices and methods for improving web safety and deterrence od cyberbullying
HK1217650A1 (zh) 用於治療劇痛的組合物及方法
AP2015008835A0 (en) Biocidal systems and methods of use
EP2956171A4 (en) METHODS OF PROTECTING AGAINST MULTIPLE SCLEROSIS AND METHODS FOR TREATING IT
EP3019151A4 (en) COMPOSITIONS AND METHOD FOR TREATING HAIR
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
SG11201510300RA (en) Compositions and methods for treating skin
HK1223021A1 (zh) 治療和預防輻射損傷的方法
HK1221913A1 (zh) 拮抗劑用於預防和/或治療骨盆-會陰功能病狀的用途
EP3019150A4 (en) COMPOSITIONS AND METHODS FOR TREATING HAIR
EP2928460A4 (en) METHODS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY SKIN DISEASES
HK1222323A1 (zh) 用於治療影響表皮的病狀的組合物和方法
HK1220396A1 (zh) 痤瘡的治療和預防
IL246185A0 (en) Methods and compositions for treating dysregulation in systems
GB201309431D0 (en) Treatment and prevention of malaria
ZA201408732B (en) Composition and methods for treating wounds